Close

Anti-PMEL TCR-NK Cells (XS-0623-ZP182)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The genetically modified anti-PMEL TCR-NK cell is designed to target to the specific epitope-HLA complex. The TCR-NK is expected to show antigen-specific cytotoxicity against PMEL antigen via the introduced TCR were successfully produced.

  Add to Cart

Specifications

  • Cell Type
  • TCR-NK
  • Host Cell Type
  • Primary NK cells

TCR Design

  • Target
  • PMEL
  • Common Name
  • PMEL
  • Target Species
  • Human
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
Sub CAT. HLA TCR Clone Epitope  
XS-0623-ZP182-SUB1 HLA-A2 296 YLEPGPVTA
XS-0623-ZP182-SUB2 HLA-A2 gp100 YLEPGPVTA
XS-0623-ZP182-SUB3 HLA-A*0201 gp100(154) KTWGQYWQV
XS-0623-ZP182-SUB4 HLA-A*0201 L2G2 aa 209-217
XS-0623-ZP182-SUB5 HLA-A*0201 MPD YLEPGPVTA
XS-0623-ZP182-SUB6 HLA-A2 PMEL17 YLEPGPVTA
XS-0623-ZP182-SUB7 HLA-A*0201 R6C12 aa 209-217
XS-0623-ZP182-SUB8 HLA-A*0201 Sp(0.01)A KTWGQYWQV
XS-0623-ZP182-SUB9 HLA-A*0201 Sp(0.01)B KTWGQYWQV
XS-0623-ZP182-SUB10 HLA-A*0201 Sp(0.01)C KTWGQYWQV
XS-0623-ZP182-SUB11 HLA-A*0201 Sp(0.01)D KTWGQYWQV
XS-0623-ZP182-SUB12 HLA-A*0201 Sp(0.01)K KTWGQYWQV
XS-0623-ZP182-SUB13 HLA-A*0201 Sp(0.1)A10 KTWGQYWQV
XS-0623-ZP182-SUB14 HLA-A*0201 Sp(1) A KTWGQYWQV
XS-0623-ZP182-SUB15 HLA-A*0201 Sp(1)B KTWGQYWQV
XS-0623-ZP182-SUB16 HLA-A*0201 Sp(5)B KTWGQYWQV
XS-0623-ZP182-SUB17 HLA-A*0201 T2(0.01)A KTWGQYWQV
XS-0623-ZP182-SUB18 HLA-A*0201 T2(1) I KTWGQYWQV
XS-0623-ZP182-SUB19 HLA-A*0201 T2(1) L KTWGQYWQV
XS-0623-ZP182-SUB20 HLA-A*0201 T2(1) R KTWGQYWQV
XS-0623-ZP182-SUB21 HLA-A*0201 T2(1) U KTWGQYWQV
XS-0623-ZP182-SUB22 HLA-A*0201 T2(1)A KTWGQYWQV
XS-0623-ZP182-SUB23 HLA-A*0201 T2(1)B KTWGQYWQV
XS-0623-ZP182-SUB24 HLA-A*0201 T2(1)C KTWGQYWQV
XS-0623-ZP182-SUB25 HLA-A*0201 T2(1)Cpost KTWGQYWQV
XS-0623-ZP182-SUB26 HLA-A*0201 T2(1)G KTWGQYWQV
XS-0623-ZP182-SUB27 HLA-A*0201 T2(1)H KTWGQYWQV
XS-0623-ZP182-SUB28 HLA-A*0201 T2(1)J KTWGQYWQV
XS-0623-ZP182-SUB29 HLA-A*0201 T2(1)K KTWGQYWQV
XS-0623-ZP182-SUB30 HLA-A*0201 T2(1)M KTWGQYWQV
XS-0623-ZP182-SUB31 HLA-A*0201 T2(1)N KTWGQYWQV
XS-0623-ZP182-SUB32 HLA-A*0201 T2(1)O KTWGQYWQV
XS-0623-ZP182-SUB33 HLA-A*0201 T2(1)P KTWGQYWQV
XS-0623-ZP182-SUB34 HLA-A*0201 T2(1)Q KTWGQYWQV
XS-0623-ZP182-SUB35 HLA-A*0201 T2(1)S KTWGQYWQV
XS-0623-ZP182-SUB36 HLA-A*0201 T2(1)T KTWGQYWQV

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-PMEL TCR-NK Cells (XS-0623-ZP182). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.